



ASX/News
Release

AVITA Medical, INC (ASX:AVH)

Results of Annual General Meeting

VALENCIA, Calif., U.S. June 3, 2026 and Melbourne, Australia, June 4, 2026 – In accordance with ASX Listing Rule 3.13.2, we advise the outcome in respect of each of the proposals put to the meeting of AVITA Medical, Inc's stockholders on June 3 (United States) / June 4, 2026 (Australia) in the attached voting results summary.

Authorized for release by the Chief Legal and Compliance Officer & Corporate Secretary of AVITA Medical, Inc.

About AVITA Medical, Inc.

AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is RECELL®, approved by the FDA for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient's own skin to create Spray-On Skin™, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to market, sell, and distribute Cohealyx®, an AVITA Medical-branded collagen-based dermal matrix, and the exclusive rights to manufacture, market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix.

In international markets, RECELL is approved to promote skin healing in a wide range of applications, including thermal burn and trauma wounds. RECELL and RECELL GO® are CE-marked in Europe and have TGA certification in Australia and are listed with Medsafe in New Zealand; RECELL is PMDA-approved in Japan.

To learn more, visit www.avitamedical.com.

Investor & Media Contact:

Ben Atkins

Phone +1-805 341 1571

investor@avitamedical.com | media@avitamedical.com

AVITA Medical, Inc.
Annual Meeting of Stockholders
June 3, 2026 (United States) / June 4, 2026 (Australia)
Voting Results

The following information is provided for the purposes of ASX Listing Rule 3.13.2

Proposal Details	Instructions given to validly appointed proxies (as at proxy close) ¹				Proposal result
Proposal	For	Against	Proxy's discretion	Abstain	Carried / not carried
Proposal 1: <i>Election of Directors to serve a one-year term:</i> Cary Vance	11,176,792 95.51%	0 0%	0 0%	525,113 4.49% (withheld)	Carried
Proposal 1: <i>Election of Directors to serve a one-year term:</i> Prof. Suzanne Crowe	10,979,194 93.82%	0 0%	0 0%	722,711 6.18% (withheld)	Carried
Proposal 1: <i>Election of Directors to serve a one-year term:</i> Jeremy Curnock Cook	10,700,424 91.44%	0 0%	0 0%	1,001,481 8.56% (withheld)	Carried
Proposal 1: <i>Election of Directors to serve a one-year term:</i> Robert McNamara	10,962,888 93.68%	0 0%	0 0%	739,017 6.32% (withheld)	Carried
Proposal 1: <i>Election of Directors to serve a one-year term:</i> Jan Stern Reed	10,902,991 93.17%	0 0%	0 0%	798,914 6.83% (withheld)	Carried
Proposal 1: <i>Election of Directors to serve a one-year term:</i> Dr. Michael Tarnoff	11,011,908 94.1%	0 0%	0 0%	689,997 5.9% (withheld)	Carried
Proposal 1: <i>Election of Directors to serve a one-year term:</i> Joseph Woody	10,977,874 93.81%	0 0%	0 0%	724,031 6.19% (withheld)	Carried
Proposal 2: <i>To ratify the appointment of Grant Thornton, LLP as the Company's independent accountants for the fiscal year ending December 31, 2026</i>	14,962,654 95.96%	225,151 1.64%	0 0%	374,642 2.4%	Carried

¹ All results in this column are identical to the for/against/abstain results required to be reported pursuant to ASX Listing Rule 3.13.2(d)

<u>Proposal 3:</u> <i>To approve, for the purposes of ASX Listing Rule 10.17 of the Australian Securities Exchange (the "ASX") and the Company's Amended and Restated Bylaws (the "Company's Bylaws") and for all other purposes, that the maximum aggregate annual cash fee pool from which the non-executive Directors of the Company may be paid for their services on the Board be increased from US\$750,000 per annum to US\$900,000 per annum;</i>	8,582,602 73.35%	2,710,656 23.16%	0 0%	408,647 3.49%	Carried
<u>Proposal 4:</u> <i>To approve the grant of 22,214 restricted stock units to acquire shares of the Company's common stock ("Common Stock") and the grant of 16,133 options to acquire shares of Common Stock to Professor Suzanne Crowe pursuant to ASX Listing Rule 10.11</i>	8,869,562 75.8%	2,411,009 20.6%	0 0%	421,334 3.6%	Carried
<u>Proposal 5:</u> <i>To approve the grant of 22,214 restricted stock units to acquire shares of the Company's common stock ("Common Stock") and the grant of 16,133 options to acquire shares of Common Stock to Jeremy Curnock Cook pursuant to ASX Listing Rule 10.11</i>	8,722,810 74.55%	2,544,450 21.74%	0 0%	434,645 3.71%	Carried
<u>Proposal 6:</u> <i>To approve the grant of 22,214 restricted stock units to acquire shares of the Company's common stock ("Common Stock") and the grant of 16,133 options to acquire shares of Common Stock to Robert McNamara pursuant to ASX Listing Rule 10.11</i>	8,818,589 75.36%	2,449,386 20.93%	0 0%	433,930 3.71%	Carried
<u>Proposal 7:</u> <i>To approve the grant of 22,214 restricted stock units to acquire shares of the Company's common stock ("Common Stock") and the grant of 16,133 options to acquire shares of Common Stock to Jan Stern Reed pursuant to ASX Listing Rule 10.11</i>	8,841,764 75.56%	2,434,253 20.80%	0 0%	425,888 3.64%	Carried

<u>Proposal 8:</u> <i>To approve the grant of 26,250 restricted stock units to acquire shares of the Company's common stock ("Common Stock") and the grant of 19,063 options to acquire shares of Common Stock to Dr. Michael Tarnoff pursuant to ASX Listing Rule 10.11</i>	8,774,530 74.99%	2,458,787 21.01%	0 0%	468,588 4%	Carried
<u>Proposal 9:</u> <i>To approve the grant of 22,214 restricted stock units to acquire shares of the Company's common stock ("Common Stock") and the grant of 16,133 options to acquire shares of Common Stock to Dr. Michael Tarnoff pursuant to ASX Listing Rule 10.11</i>	8,791,498 75.13%	2,433,367 20.79%	0 0%	477,040 4.08%	Carried
<u>Proposal 10:</u> <i>To approve the grant of 40,547 restricted stock units to acquire shares of the Company's common stock ("Common Stock") and the grant of 29,446 options to acquire shares of Common Stock to Joseph Woody pursuant to ASX Listing Rule 10.11</i>	8,830,204 75.46%	2,446,817 20.91%	0 0%	424,884 3.63%	Carried
<u>Proposal 11:</u> <i>To approve the grant of 22,214 restricted stock units to acquire shares of the Company's common stock ("Common Stock") and the grant of 16,133 options to acquire shares of Common Stock to Joseph Woody pursuant to ASX Listing Rule 10.11</i>	8,863,312 75.74%	2,395,376 20.47%	0 0%	443,217 3.79%	Carried
<u>Proposal 12:</u> <i>To approve, on an advisory basis, the compensation of our named executive officers</i>	8,918,272 76.21%	2,202,213 18.82%	0 0%	581,420 4.97%	Carried
<u>Proposal 13:</u> <i>To approve, on an advisory basis, the frequency of future advisory votes on executive compensation</i>	1YR: 9,545,151 81.57% 2YRS 924,743 7.9% 3YRS 650,252 5.56%	N/A	0 0%	581,759 4.97%	Carried (1YR)

Proposal 14: <i>To approve, for the purpose of ASX Listing Rule 7.1 and all other purposes, the issuance of a warrant or warrants covering up to 650,000 shares of Common Stock, with a term of ten years, to Perceptive Credit Holdings V, LP ("Perceptive"), pursuant to the Credit Agreement between the Company and Perceptive, dated January 13, 2026</i>	9,322,532 79.67%	1,769,627 15.12%	0 0%	609,746 5.21%	Carried
Proposal 15: <i>To approve as a special resolution, for the purpose of ASX Listing Rule 7.1A and all other purposes, the issue of Equity Securities (as defined in ASX Listing Rule 19.2) up to 10% of the issued capital (at the time of issuance) of the Company, calculated in accordance with ASX Listing Rule 7.1A.2</i>	8,947,195 76.46%	2,223,106 19%	0 0%	531,604 4.54%	Carried